International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

RNA as Medicine: The Pharmacological Revolution of Therapeutic Oligonucleotides: A Review Article

Puneet Kashyap[1], Gunjan Khurana[2], Biswadeep Das[3], Manisha Bisht[4]

[1,2,3,4]Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India

Abstract

Therapeutic oligonucleotides have matured into clinically validated medicines across neurology, hepatic/metabolic disease, cardiometabolic risk, and infectious disease. Antisense oligonucleotides (ASOs) act via RNase H–mediated degradation or splice modulation, with intrathecal splice-switching improving motor outcomes in spinal muscular atrophy and exhibiting month-scale CNS tissue half-lives. Gapmer ASOs that suppress transthyretin (TTR) synthesis deliver meaningful neuropathy improvements but require platelet and renal monitoring consistent with phosphorothioate backbones. Small interfering RNAs (siRNA) achieve potent, durable hepatic gene silencing through two delivery paradigms: subcutaneous N-acetylgalactosamine (GalNAc) conjugates with short plasma but long hepatic residence enabling quarterly to twice-yearly maintenance, and intravenous lipid nanoparticles (LNPs) that provide efficient hepatic uptake with manageable infusion reactions. Clinically, this translates to large attack reductions in acute hepatic porphyria, sustained ~50% LDL-C lowering with twice-yearly dosing in hypercholesterolemia, and ~90% TTR reduction with functional benefit in amyloidosis. mRNA vaccines using N1-methylpseudouridine and LNPs demonstrated rapid design-to-clinic timelines and high efficacy at population scale, establishing a manufacturable platform now extending toward therapeutic mRNA applications. Safety profiles largely reflect chemistry and delivery and are mitigable by sequence design, dosing strategies, premedication (for IV LNPs) - and routine laboratory monitoring. Extrahepatic targeting, stereo-controlled chemistries that enhance the potency without class toxicity and model based interval selection can expand organ reach and therapeutic breadth.

Keywords: Therapeutic oligonucleotides; antisense oligonucleotides; siRNA; lipid nanoparticles; pharmacokinetics/pharmacodynamics.

Introduction

Therapeutic oligonucleotides have moved from concept to clinic and reshaped how we modulate disease biology at the RNA level.[1,2] In a little over a decade - antisense oligonucleotides (ASOs) and small-interfering RNAs (siRNA) have established durable clinical benefit across neurology and hepatic/metabolic diseases.[3,4] mRNA vaccines demonstrated platform speed and scale during the COVID-19 pandemic.[5–8] This transition has been powered by medicinal-chemistry advances i.e., phosphorothioate (PS) backbones and 2′-substitutions (2′-MOE/2′-OMe, LNA); and by delivery innovations such as triantennary GalNAc conjugation for hepatocyte targeting and lipid nanoparticles (LNPs) for systemic mRNA/siRNA administration.[5,7,9,10] These design rules have made exposure, tissue distribution and

targeted activity more predictable. This has enabled practical subcutaneous or intrathecal dosing schedules and longer pharmacodynamic persistence in target organs.[5,7]

Clinical exemplars now form the basis for the field's pharmacology. In neurology - splice-modifying ASOs for spinal muscular atrophy delivered clear functional gains versus sham, validating exon targeting in the central nervous system via intrathecal delivery.[11] In systemic protein misfolding disorders - an ASO that reduces transthyretin synthesis improved neuropathy outcomes but also revealed class-typical risks of thrombocytopenia and glomerulonephritis that are manageable with monitoring.[5,12] In parallel - siRNA drugs have shown robust and durable hepatic gene silencing using GalNAc, including marked reductions in disease attacks for acute hepatic porphyria and sustained LDL-C lowering via PCSK9 suppression with twice-yearly dosing.[7,13,14] LNP-delivered siRNA and mRNA have complemented this conjugate approach by allowing for intravenous delivery and rapid expression/silencing kinetics at the liver.[8,10]

The pharmacokinetic/pharmacodynamic (PK/PD) provides a coherent perspective. After subcutaneous administration - GalNAc-siRNA typically exhibit short plasma half-lives but prolonged hepatic residence and intracellular stability, driving infrequent maintenance dosing; intrathecal ASOs achieve central exposure with tissue half-lives measured in months; and LNP-mRNA produces rapid hepatic uptake with transient expression peaks.[6,7,10,11] Exposure–response relationships commonly plateau as intracellular machinery (RISC loading or RNase H engagement) saturates, an attribute that supports model-informed dose and interval selection in development and practice.[6,7] Safety profiles are influenced by both the chemistry and delivery: PS-rich ASOs can associate with thrombocytopenia and renal events; siRNA/ASO classes require hepatic monitoring; and innate immune activation via TLRs or complement is minimized by modern chemistries and dosing practices.[5,6,12,14]

The landscape has widened beyond ASO/siRNA and mRNA. Renewed clinical momentum in microRNA therapeutics is making use of improved chemistries and formulations to revisit oncology and fibrotic indications (Kim et al. (2023)). Aptamers e.g., ligand-like oligonucleotides that bind extracellular targets are re-emerging with better stabilization and conjugation strategies, particularly for targeted cancer therapy.[15–19] Extrahepatic delivery are the field's defining frontier - with material and ligand-engineered systems seeking reliable access to lung, tumour and CNS parenchyma.[9,20,21]

This review takes a pharmacology-first approach tailored to clinicians and translational researchers. We synthesize (i) class mechanisms and clinical exemplars; (ii) chemistry and structural modifications that tune potency, stability, and safety; (iii) delivery systems and tissue targeting with a focus on extrahepatic strategies; (iv) PK/PD and ADME principles that guide regimen design; (v) safety and immunogenicity themes with risk-mitigation strategies; and (vi) the evolving clinical and regulatory landscape.

Methodology

This article is a narrative review based on synthesis of peer-reviewed literature and publicly available regulatory sources to provide an overview of antisense oligonucleotide (ASO) pharmacology and a comparative analysis of FDA/EMA-approved and clinically advanced oligonucleotide medicines. The authors frame the scope around ASO mechanisms, medicinal-chemistry modifications (e.g., phosphorothioate backbones; 2′-substitutions; gapmers/BNAs), delivery strategies, and therapeutic products, then collate clinical and regulatory information for marketed agents. Evidence is integrated thematically (mechanism → chemistry → delivery → products), drawing on primary publications and regulator documentation cited in the text/figures (e.g., the section and figure summarizing oligonucleotide drugs approved by FDA and EMA).

Search strings used:

(("Oligonucleotides, Antisense"[Mesh] OR "RNA, Antisense"[tiab] OR "antisense oligonucleotide*"[tiab] OR ASO[tiab]) AND (pharmacology[tiab] OR pharmacokinetic*[tiab] OR "PK/PD"[tiab] OR ADME[tiab] OR safety[tiab] OR immunogenicity[tiab] OR clinical[tiab] OR approval[tiab] OR "drug labeling"[tiab] OR "product label"[tiab] OR "assessment report"[tiab] OR delivery[tiab]) AND (phosphorothioate[tiab] OR "2'-O-methoxyethyl"[tiab] OR "2'-MOE"[tiab] OR LNA[tiab] OR "bridged nucleic acid"[tiab] OR GalNAc[tiab] OR "N-acetylgalactosamine"[tiab] OR "lipid nanoparticle*"[tiab] OR LNP[tiab])) AND (2019/01/01:2025/10/31[dp]) AND (English[lang]) AND (Review[ptyp] OR "Clinical Trial, Phase II"[ptyp] OR "Clinical Trial, Phase III"[ptyp] OR "Observational Study"[ptyp] OR "Practice Guideline"[ptyp] OR "Government Publications"[ptyp])

Data has been summarized qualitatively to emphasize mechanistic plausibility, platform advances (e.g., PS/2′-modifications, GalNAc conjugation) and clinical outputs from key trials and labels.

Figure 1 - Structure of the review



Therapeutic Oligonucleotide Classes

Antisense oligonucleotides (ASOs): Finkel et al. (2017) evaluated intrathecal nusinersen for infantile-onset spinal muscular atrophy in a randomized, sham-controlled trial. Infants received loading and maintenance doses (12 mg IT) with motor function assessed by standardized milestone scales and survival without permanent ventilation as key outcomes.[11] Nusinersen produced a 51% motor milestone response vs 0% with sham and reduced the hazard of death or permanent ventilation (HR ≈ 0.53). Pharmacologically, central exposure was prolonged with CNS tissue half-life ~135–177 days. This supported infrequent maintenance dosing. Safety indicated the procedure (lumbar puncture–related events) without excess systemic toxicity. The trial established that splice-modulating ASOs can durably alter disease trajectory in the CNS with manageable risk.[11]

Benson et al. (2018) tested subcutaneous inotersen (an RNase H-active gapmer against TTR) in adults with hATTR polyneuropathy in a randomized, placebo-controlled study. Weekly dosing led to serum TTR reductions ≈74% and superior clinical outcomes (mNIS+7 Δ −19.7 vs −8.8 at 66 weeks). Class-typical adverse events—thrombocytopenia and glomerulonephritis—were observed but controlled with monitoring algorithms. Together with the broader synthesis by Collotta et al. (2023) and clinical pharmacology guidance from Rogers et al. (2021) - these studies showed that PS-backbone/2′-MOE ASOs deliver predictable exposure based response when dosing and safety labs are standardized.[5,6,12]

Small interfering RNA (siRNA): Adams et al. (2018) studied patisiran (LNP-formulated siRNA against TTR mRNA) in adults with hATTR amyloidosis in a double-blind phase 3 trial. Intravenous LNP infusions achieved hepatic delivery with ~90% serum TTR reduction, translating to marked clinical benefit (mNIS+7 Δ −34.0 vs −5.8, p<0.001; quality-of-life improvements). Infusion reactions (~20% vs 10% placebo) were manageable with premedication, demonstrating that LNP-siRNA can be safely and repeatedly administered.[10]

Balwani et al. (2020) evaluated givosiran (GalNAc-conjugated siRNA to ALAS1) in acute hepatic porphyria. Monthly subcutaneous injections produced ~80–90% urinary ALA suppression and a 74% reduction in annualized porphyria attacks (3.2 vs 12.5/yr). Adverse events included ALT/AST elevations and creatinine increases, aligning with on-target hepatic exposure; risk was mitigated by laboratory monitoring.[13]

Ray et al. (2020) examined inclisiran (GalNAc-siRNA to PCSK9) in hypercholesterolemia. A day-1/day-90 loading then q6-month regimen (300 mg SC) delivered ~50% sustained LDL-C reduction to 18 months with injection-site reactions ~5% and otherwise favorable tolerability.

From a mechanistic perspective - McDougall et al. (2022) showed that GalNAc-siRNA exhibited short plasma but longer hepatic half-lives with highly predictable cross-species PK/PD – this allows for infrequent dosing and straightforward translation. Safety and chemistry principles summarized by Rogers et al. (2021) and Liu et al. (2025) explain why 2′-F/2′-OMe sugars and end-caps balance stability, potency and innate immune quiescence.[6,7,9]

microRNA (miRNA) therapeutics: Kim et al. (2023) reviewed clinical trends for miRNA mimics (restoring tumour-suppressive miRNAs) and antimiRs (inhibiting oncogenic miRNAs). They highlighted lessons from early setbacks and the resurgence enabled by improved 2′-modifications, optimized carriers, and tighter patient selection.[22] Emerging oncology and fibrotic programs emphasize network-level modulation with careful dosing to avoid excessive innate activation. In practice this means designing sequences and formulations to titrate multi-gene effects safely, an approach consistent with pharmacology guidance from Rogers et al. (2021) and the broader modality landscape in Liu et al. (2025).[9]

Aptamers: Mahmoudian et al. (2024) synthesized advances in therapeutic aptamers as extracellular, high-affinity RNA/DNA ligands for targeted cancer therapy.[19] The review details how chemical stabilization, multimerization, and payload conjugation improve half-life, tumour penetration, and pharmacologic durability. With immunostimulation generally modest under modern 2′-modifications and selection stringency, aptamers function as ligand-like antagonists or delivery handles, expanding options where receptor density and accessibility are favorable. The broader toolkit summarized by Liu et al. (2025) places aptamers along with ASOs/siRNA as complementary mechanisms rather than competitors.[9]

mRNA vaccines/therapeutics: Polack et al. (2020) reported the pivotal randomized trial of the BNT162b2 mRNA vaccine, using N1-methylpseudouridine–modified mRNA in LNPs. Two intramuscular doses yielded 95% vaccine efficacy (8 cases vs 162 placebo; N=43,548) with a well-characterized safety profile (reactogenicity common, serious events rare and balanced).[8] Expression kinetics e.g., rapid rise and decay over days match the immune-priming objective and are governed by RNA stability and LNP design – these principles are similar in therapeutic mRNA development as narrated by Adams et al. (2018) and Liu et al. (2025). As formulation science evolves, extrahepatic targeting frameworks from Paunovska et al. (2022) are informing next-generation mRNA medicines beyond vaccines.[9,10,20]

Across modalities - chemistry defines stability and innate profile, delivery sets cell access and durability, and together they determine dose, interval, and risk. This is a pattern consistently observed across clinical exemplars.[5–7]

Chemistry and Structural Modifications

Backbone engineering (phosphorothioate, PS): Replacing a non-bridging oxygen with sulphur increases nuclease resistance and plasma protein binding, prolonging circulation and shaping tissue exposure.[5,6] This same interaction profile explains class-typical platelet and renal signals with PS-rich gapmers—manageable with structured labs and dose algorithms.[5,12]

Sugar modifications (2′-O-substitutions and LNA): Rogers et al. (2021) summarized how 2′-O-methoxyethyl (2′-MOE) and 2′-O-methyl (2′-OMe) raise affinity and damp innate sensing while keeping RNase H or splice-switching mechanisms intact; Collotta et al. (2023) extended this to emphasize practical design windows that avoid over-stabilization.[5] In the CNS, 2′-MOE/PS architectures underpinned intrathecal splice-switching with month-scale tissue half-lives and functional benefit.[11] Locked nucleic acids (LNA) further increase melting temperature and potency but must be titrated to avoid sequence- and chemistry-related liabilities at high content.[5,6]

siRNA stabilization (2′-F/2′-OMe; terminal PS; end-caps): Modern siRNA duplexes use 2′-fluoro/2′-OMe sugars plus terminal PS and end-caps to resist nucleases and reduce missed targets while preserving RISC loading. McDougall et al. (2022) showed that with this chemistry, hepatic knockdown becomes highly predictable across species, enabling long-interval subcutaneous regimens.[6,7,9]

Conjugation for targeting (GalNAc): McDougall et al. (2022) quantified how triantennary GalNAc drives high-capacity ASGPR uptake in hepatocytes, yielding short plasma but long hepatic half-lives and consistent exposure–response. Ray et al. (2020) translated this into practice with inclisiran (PCSK9), demonstrating ~50% sustained LDL-C reduction on day-1/day-90 loading then q6-month dosing. In acute hepatic porphyria, Balwani et al. (2020) used the same conjugation logic for givosiran to suppress ALA ~80–90% and cut attack rates by ~74%. These studies define GalNAc as the basis for liver-directed oligos.[7,13,14]

Architectures (gapmers and splice-switchers): Gapmers place a DNA-like core between modified "wings" to recruit RNase H while maintaining stability.[23,24] Splice-switchers rely on high-affinity binding to redirect exon usage without cleavage.[5,6] Benson et al. (2018) exemplified the gapmer approach in hATTR with robust TTR suppression and manageable PS-linked toxicities under monitoring - while Finkel et al. (2017) established splice-switching efficacy in SMA.[11,12]

LNP/mRNA chemistry: Adams et al. (2018) detailed the ionizable lipid + helper lipid + cholesterol + PEG-lipid recipe that enables endosomal escape and hepatic delivery for oligo cargoes. For coding RNA, N1-methylpseudouridine reduces innate sensing and improves translation; Polack et al. (2020) then demonstrated this chemistry-formulation pairing at scale with high vaccine efficacy and a well-characterized safety profile. These design principles now inform therapeutic mRNA beyond vaccines.[8,10]

Aptamer stabilization: Mahmoudian et al. (2024) reviewed how 2′-modifications, multimerization, and payload conjugation extend half-life, enhance avidity, and improve tumour penetration, positioning aptamers as extracellular antagonists or delivery ligands in oncology. The broader nucleic-acid toolkit summarized by Liu et al. (2025) places aptamers alongside ASOs/siRNA as complementary rather than competing mechanisms.[9,19]

Design trade-offs and stereochemistry: Across modalities, higher affinity/stability improves potency and durability but can increase protein binding or off-target effects if over-applied (Rogers et al. (2021); Collotta et al. (2023)). Emerging stereocontrolled backbones and next-gen analogues aim to lift potency while minimizing class liabilities; optimal outcomes come from chemistry chosen with delivery in mind—GalNAc for hepatocytes, LNPs for systemic RNA, and ligand/antibody conjugation for extrahepatic reach.[5–7,20]

Delivery Systems and Tissue Targeting

Intrathecal delivery to the CNS: Finkel et al. (2017) evaluated intrathecal nusinersen (12 mg) for infantile-onset SMA and showed a 51% motor-milestone response vs 0% with sham, with CNS tissue half-lives ~135–177 days supporting infrequent maintenance dosing. Procedure-related events predominated without excess systemic toxicity, illustrating how direct CSF exposure delivers durable splice correction when the target resides in the CNS.[11]

Hepatocyte targeting with GalNAc (subcutaneous): McDougall et al. (2022) demonstrated that triantennary GalNAc drives high-capacity ASGPR uptake, yielding short plasma but long hepatic half-lives and highly predictable cross-species PK/PD. In acute hepatic porphyria, Balwani et al. (2020) reported that monthly givosiran produced ~80–90% urinary ALA suppression and a 74% attack reduction (3.2 vs 12.5 per year), with ALT/AST elevations, mild creatinine increases, and injection-site reactions handled by routine monitoring (Balwani et al. (2020); Dickey et al. (2024)). Inclisiran operationalizes the same principle: Ray et al. (2020) used a day-1/day-90 loading then q6-month regimen (300 mg SC) to sustain ~50% LDL-C reduction with mostly mild local reactions (~5%). Chemistry—2′-F/2′-OMe sugars with terminal PS linkages—helps balance stability, on-target potency, and low innate activation.[6,9,13,14,21]

Lipid nanoparticles (LNP) for intravenous hepatic delivery: Adams et al. (2018) studied patisiran and showed that IV LNP-siRNA achieves potent hepatic uptake and ~90% serum TTR reduction, translating to mNIS+7 Δ −34.0 vs −5.8 ($p<0.001$) and improved quality-of-life; infusion reactions (~20% vs 10% placebo) were manageable with premedication (Adams et al. (2018)). This IV paradigm prioritizes rapid onset and peak potency when infusion logistics are acceptable.[5,6,10]

LNPs for intramuscular mRNA delivery: Polack et al. (2020) reported that N1-methylpseudouridine–modified mRNA in LNPs, delivered intramuscularly, achieved 95% efficacy (8 vs 162 cases; N=43,548) with a well-characterized reactogenicity profile and rare serious AEs balanced across arms (Polack et al. (2020)). The same ionizable-lipid/PEG-lipid/cholesterol framework governs endosomal escape and expression kinetics, which peak within hours to days—features now being adapted for therapeutic mRNA beyond vaccines.[8,9,20]

Route–system matching (putting it together): For CNS targets, intrathecal delivery provides durable tissue exposure and clinical benefit (Finkel et al. (2017)). For hepatocyte targets, SC GalNAc enables long-interval dosing with routine hepatic/renal labs while maintaining robust on-target knockdown. When IV access is feasible and rapid onset is desired, LNP-siRNA is practical with premedication for infusion reactions.[7,10,13,14] For immunization or local protein expression, IM LNP-mRNA achieves scalable responses with predictable reactogenicity.[8] Across modalities, delivery dictates cell access and durability, while chemistry tunes potency and innate profile.[5,6]

Pharmacokinetics, Pharmacodynamics, and ADME

Absorption and distribution: Route dictates early disposition. Finkel et al. (2017) showed that intrathecal dosing of a splice-modifying ASO achieves direct CSF exposure with CNS tissue half-lives ~135–177 days, explaining infrequent maintenance once milestones stabilize.[11] For subcutaneous GalNAc-siRNA, McDougall et al. (2022) demonstrated rapid hepatic uptake via ASGPR, short plasma but long hepatic residence, and highly predictable cross-species PK/PD. This is a pattern that underlies quarterly or twice-yearly regimens.[7] Intravenous LNP-siRNA and intramuscular LNP-mRNA distribute quickly to reticuloendothelial/lymphoid tissues where ionizable lipids facilitate endosomal escape and intracellular release.[8,10]

Intracellular trafficking and effect kinetics: McDougall et al. (2022) mapped GalNAc-siRNA journey from clathrin-mediated endocytosis to endosomal escape and RISC loading, with durable intracellular residence driving long pharmacodynamic tails.[7] Adams et al. (2018) showed that LNP-siRNA produces ~90% serum TTR reduction with functional gains, indicating efficient hepatic delivery and sustained RISC engagement.[10] For mRNA, Polack et al. (2020) reported rapid protein expression over hours–days that decays with RNA turnover—kinetics well suited to immunization windows.[8]

Dose, interval, and exposure–response: Ray et al. (2020) used a day-1/day-90 loading then q6-month schedule (300 mg SC) for inclisiran, achieving ~50% LDL-C reduction through durable PCSK9 suppression. This interval is supported by intracellular persistence rather than long plasma half-life. Balwani et al. (2020) showed that monthly givosiran yields ~80–90% urinary ALA suppression and −74% attacks, with the maintenance frequency reflecting hepatic residence and target turnover. Exposure–response often plateaus as RISC loading or RNase H engagement saturates, which is why model-informed dosing focuses on interval optimization more than incremental dose escalation.[6,7,13,14]

Metabolism and elimination: ASOs and siRNA undergo stepwise endonuclease/exonuclease trimming to shorter oligos and nucleosides; elimination occurs via renal and biliary routes depending on size, charge, and protein binding.[6] For ASOs, PS content and 2′-substitutions increase protein binding and reduce filtration, extending exposure in target tissues. For LNP-RNA, lipid components are metabolized hepatically while released RNA follows normal nucleotide catabolism.[5,6,10]

DDI, special populations, and translational considerations: Rogers et al. (2021) reviewed clinical pharmacology packages and reported low drug–drug interaction potential, limited CYP involvement, and

sparse organ-impairment data relative to small molecules; routine cardiac evaluation was advised in development datasets without consistent PK impact. Immunogenicity typically does not alter exposure or efficacy for approved siRNA/ASO programs when modern chemistries and premedication are used, though hepatic labs and renal monitoring remain prudent.[6,7]

Key numeric anchors from clinical exemplars: Intrathecal ASO: CNS t½ ~135–177 days and 51% responder rate in infantile-onset SMA (Finkel et al. (2017)). LNP-siRNA (IV): ~90% TTR reduction with significant functional improvement in hATTR.[10,11] GalNAc-siRNA (SC): ALA suppression ~80–90% and −74% attacks in AHP; ~50% LDL-C reduction with twice-yearly inclisiran maintenance. These anchors illustrate how intracellular persistence, not plasma t½, sets interval, a theme consistent across liver-directed oligonucleotides.[6,7,13,14]

Safety and Immunogenicity

Class overview: Oligonucleotide safety reflects chemistry + delivery + sequence. Rogers et al. (2021) reviewed clinical pharmacology packages and reported low DDI potential, limited CYP involvement, and generally minimal impact of immunogenicity on PK/efficacy, while recommending routine cardiac evaluation during development datasets (Rogers et al. (2021)). Across approved agents, innate immune activation is largely tempered by modern 2′-modifications and dosing practices.[5,6]

ASOs: platelet and renal signals: Benson et al. (2018) observed thrombocytopenia and glomerulonephritis with subcutaneous inotersen, events managed through platelet/renal monitoring and risk algorithms; these effects are consistent with phosphorothioate (PS) protein-binding profiles in gapmers and are highlighted in class reviews. In the CNS, intrathecal splice-switching produced procedure-related events without material systemic toxicity, aligning with local exposure and very long tissue half-lives.[5,11,12]

siRNA—GalNAc (SC): hepatic labs and local reactions: Balwani et al. (2020) reported that givosiran (monthly, SC) achieved ~80–90% urinary ALA suppression and −74% porphyria attacks but required monitoring for ALT/AST elevations, mild creatinine increases, and injection-site reactions; subsequent clinical experience and focused reviews emphasize on-target hepatic exposure as the mechanistic basis. For inclisiran, Ray et al. (2020) showed injection-site reactions ~5% with otherwise favorable tolerability on a day-1/day-90 then q6-month schedule, illustrating how ligand-directed uptake enables long intervals without cumulative systemic toxicity.[13,14,21]

siRNA—LNP (IV): infusion reactions, premedication: Adams et al. (2018) demonstrated that patisiran infusions were associated with infusion-related reactions (~20% vs 10% placebo), effectively mitigated by premedication; the signal profile otherwise indicated potent hepatic delivery with ~90% TTR reduction and meaningful functional benefit.[10]

mRNA (IM LNP): reactogenicity and rare serious AEs: Polack et al. (2020) reported a well-characterized reactogenicity profile (local pain, fatigue, headache) and rare serious adverse events balanced between vaccine and placebo in the BNT162b2 trial. Expression windows of hours–days, combined with N1-methylpseudouridine and optimized LNPs, contain innate activation while achieving robust immunogenicity.[8,9]

Mechanistic mitigations (design knobs): Rogers et al. (2021) summarized how 2′-OMe/2′-MOE/LNA and controlled PS content reduce TLR/complement engagement; McDougall et al. (2022) emphasized that GalNAc confines exposure to hepatocytes with short plasma but long hepatic half-lives, enabling interval-

driven risk control. In practice, safety management relies on sequence screening, conservative PS loading, premedication for IV LNPs, and lab monitoring aligned to organ exposure.[5–7]
Across modalities most risks are predictable from chemistry and delivery and are mitigable with dosing, sequence design, and monitoring—hence the low DDI potential and stable exposure–response profiles seen in regulatory submissions.[5,6]

Clinical landscape & indications

Neurology — CNS splice modulation (ASOs): Finkel et al. (2017) evaluated intrathecal nusinersen (12 mg) for infantile-onset SMA in a randomized, sham-controlled trial and demonstrated a 51% motor-milestone response vs 0% with sham, alongside a reduced hazard of death or permanent ventilation (HR ≈ 0.53). Month-scale CNS tissue half-lives (~135–177 days) explain durable pharmacodynamics under a loading-then-maintenance schedule and justify interval-driven dosing rather than high cumulative exposure. In practice, safety is dominated by procedure-related events, with no material systemic toxicity—consistent with localized CNS exposure.[6,11]

Systemic protein misfolding - hATTR amyloidosis (ASO and siRNA): Benson et al. (2018) tested inotersen (weekly SC, RNase-H gapmer) and achieved ~74% serum TTR reduction with superior neuropathy outcomes (mNIS+7 Δ −19.7 vs −8.8 at 66 weeks).[12] Thrombocytopenia and glomerulonephritis emerged as class-typical PS-linked risks, mitigated by structured monitoring.[5,12] Adams et al. (2018) studied patisiran (IV LNP-siRNA) and showed ~90% serum TTR reduction with major functional benefit (mNIS+7 Δ −34.0 vs −5.8; $p<0.001$) and infusion reactions ~20% vs 10% placebo, manageable with premedication.[10] When considered together, these programs validate two efficacious TTR-lowering strategies with distinct operational profiles i.e., weekly SC monitoring for ASO vs intermittent IV with premedication for LNP-siRNA.[10,12]

Hepatic/metabolic & cardiometabolic disease — GalNAc-siRNA: Balwani et al. (2020) reported that givosiran (monthly SC; ALAS1) provided a ~80–90% urinary ALA suppression and a 74% reduction in annualized porphyria attacks (3.2 vs 12.5/yr).[13] ALT/AST elevations, mild creatinine increases and injection-site reactions were handled via routine labs [13,21] Ray et al. (2020) used inclisiran (PCSK9) with day-1/day-90 loading, then q6-month 300 mg SC, achieving ~50% sustained LDL-C reduction to 18 months and injection-site reactions ~5%.[14] These outcomes illustrate how GalNAc targeting produces short plasma but long hepatic residence and highly predictable cross-species PK/PD that set long maintenance intervals.[7]

Infectious diseases — mRNA vaccines/therapeutics (LNP-mRNA): Polack et al. (2020) reported 95% efficacy for BNT162b2 (8 vs 162 cases; N = 43,548) with a well-characterized reactogenicity profile and rare serious adverse events balanced between groups. The platform relies on N1-methylpseudouridine–modified mRNA in LNPs, with expression peaking over hours–days, a kinetic profile that matches immunization goals and is now being adapted to therapeutic mRNA programs.[8,9]

Oncology and emerging areas — miRNA & aptamers: Kim et al. (2023) summarized renewed clinical momentum for miRNA therapeutics (mimics and antimiRs) as improved 2′-modifications and carriers address earlier delivery/toxicity barriers. This enabled network-level modulation in oncology and fibrotic indications.[22] Mahmoudian et al. (2024) reviewed aptamer advances—stabilization, multimerization, and payload conjugation—that improve half-life, avidity, and tumour penetration, positioning aptamers as extracellular antagonists or targeting ligands in solid tumours.[19]

Cross-indication synthesis: Across these programs, intracellular persistence—rather than plasma t½—sets the dosing interval for liver-directed oligonucleotides; GalNAc-siRNA consistently show short plasma but long hepatic half-lives with predictable exposure–response, enabling quarterly to twice-yearly maintenance.[7] Selection of route + system follows the pharmacologic job: IT for CNS splice correction, SC GalNAc for hepatocyte knockdown, IV LNP for potent hepatic siRNA when infusion logistics are acceptable, and IM LNP-mRNA for scalable immunization—while chemistry choices tune potency and innate profile.[5,6]

Regulatory, access & cost

Pathways and precedent: Rogers et al. (2021) reviewed clinical pharmacology packages submitted to regulators and noted low DDI potential, limited CYP involvement. They also reported an emphasis on exposure–response, special-population bridging and cardiac safety evaluation in filings.[6] Across modalities it is seen that programs have progressed through expedited mechanisms when biomarker/clinical efficacy align. This is quite evident in approvals spanning ASOs, siRNA, and mRNA platforms.[5,9]

What labels emphasize (monitoring themes): Benson et al. (2018) exemplified ASO label themes i.e., platelet and renal monitoring to manage thrombocytopenia and glomerulonephritis. This indicated PS-linked protein binding and class liabilities.[5,12] For GalNAc-siRNA, Balwani et al. (2020) and Dickey et al. (2024) emphasized the hepatic labs (ALT/AST), renal signals (creatinine/eGFR) and injection-site reactions – which is consistent with concentrated hepatocyte exposure and SC dosing.[13,21] With LNP-siRNA, Adams et al. (2018) showed that infusion reactions (~20% vs 10% placebo) are mitigated by premedication and infusion controls, a pattern reflected in IV RNA labels.[10] For LNP-mRNA, Polack et al. (2020) documented a reactogenicity-forward profile with rare serious AEs balanced across arms, aligning with public-health deployment needs.[8]

Quantitative anchors reported in reviews: Collotta et al. (2023) summarized regulatory traction with FDA/EMA approvals (e.g., 13 ASOs in the US; 8 in the EU) and class safety patterns.[5] Liu et al. (2025) reported 11 ASOs, 6 siRNAs, and 2 aptamers approved globally within their survey scope; counts vary by cut-off date and categorization but collectively showed a broadening regulatory footprint.[5]

Pharmacovigilance and real-world data (RWD): Rogers et al. (2021) highlighted that immunogenicity generally does not alter exposure or efficacy for approved oligos when modern chemistries/premedication are used. But ongoing PV focuses on hepatic, renal, platelet, and infusion-related signals as usage scales into broader populations.[6] Real-world extensions of the pivotal programs (e.g., inclisiran's q6-month maintenance and givosiran's monthly schedule) enable registry-based evaluation of adherence, interval durability, and lab monitoring burden.[7,13,14]

CMC/manufacturing and platform learnings: Adams et al. (2018) detailed how ionizable lipids + helper lipids + cholesterol + PEG-lipid underpin scalable LNP processes, while Polack et al. (2020) demonstrated global platform manufacturing and distribution for LNP-mRNA—capabilities now informing therapeutic mRNA development.[8,10] For GalNAc-siRNA - McDougall et al. (2022) linked predictable cross-species PK/PD to simpler dose/interval selection and smaller, faster trials; chemistry and conjugation standardization reduce development uncertainty relative to bespoke small molecules.[6,7]

Access and cost considerations: Long-interval maintenance (e.g., inclisiran 300 mg SC day-1/day-90 then q6 months) supports adherence and clinic throughput but concentrates value assessment on effect durability and monitoring needs.[7,14] Monthly givosiran requires labs but delivers large attack and

biomarker reductions. This provides cost–benefit modelling in rare disease.[13,21] For LNP-mRNA, population-scale evidence of efficacy and safety lowers uncertainty but shifts cost discussions to supply chain resilience, cold chain, and booster policy.[8] Across the modalities - payers and HTA bodies weigh administration logistics, laboratory monitoring and interval-driven durability against drug acquisition costs, with platform CMC maturity being viewed as a de-risking factor.[5,6]

Regulatory success has followed mechanism-anchored efficacy plus predictable PK/PD; labels mirror chemistry-delivery risks; and access hinges on interval durability, monitoring footprint, and scalable CMC. This is a consistent pattern across ASOs, siRNA (GalNAc/LNP), and mRNA.[5,6]

Future directions

Extrahepatic delivery as the defining frontier. Paunovska et al. (2022) outlined design rules—particle size, ionizable pKa, PEG density, ligand valency, and route—that collectively shift tropism beyond hepatocytes by improving endothelial transit and endosomal escape.[20] Liu et al. (2025) expanded on these principles and surveyed ligand-decorated LNPs, polymeric carriers, exosomes and local routes (e.g., inhalation, intrathecal) as the leading strategies for lung, tumour and deep CNS access.[9,20] In parallel – focussed/specific conjugates (e.g., receptor-binding peptides/antibodies) and antibody–oligonucleotide conjugates aim to replicate GalNAc-like efficiency outside the liver as noted by Paunovska et al. (2022).[20]

Smarter chemistry: Rogers et al. (2021) emphasized that potency gains from 2′-O-substitutions and LNA must be balanced against protein binding and innate sensing.[6] Collotta et al. (2023) further highlighted stereocontrolled backbones and next-gen analogues to lift activity while trimming class liabilities.[5] Increasing use of context-dependent PS loading, mixed-chemistry wings, and sequence screens are expected in the future - to minimize thrombocytopenia and renal signals while preserving RNase H or RISC efficiency.[5,6,25]

Programmable combinations and multi-modal designs: Aptamers are poised to act as both drugs and delivery handles, enabling receptor blockade and payload ferrying in oncology; recent reviews catalogue multimerization and payload conjugation to boost avidity and tumour penetration.[19] Combination regimens that layer oligo + antibody or small molecule can widen therapeutic windows (e.g., siRNA knockdown plus pathway inhibition). mRNA + protein/viral vectors may focus the immune profiles for infection and cancer.[9,19]

Quantitative pharmacology and interval optimization: McDougall et al. (2022) showed that for GalNAc-siRNA the short-plasma/long-hepatic profile leads to predictable cross-species PK/PD; model-informed development will keep shifting emphasis from dose escalation to interval selection anchored in intracellular residence and target turnover.[26–28] The same logic is extending to CNS ASOs and LNP-mRNA where tissue half-life or expression windows, not plasma t½, determine maintenance cadence.[6,7]

AI-assisted design and manufacturing scale: Liu et al. (2025) described AI use in sequence optimization, off-target minimization, and materials discovery, accelerating design-build-test cycles and improving extrahepatic prospects.[9] On the CMC side - LNP platform learnings from population-scale deployment and standardized GalNAc synthesis are lowering uncertainty in supply, analytics and tech transfer.[29,30] This is setting the stage for faster, de-risked programs.[7,8,10]

Figure 2 - Study Flow and Outcomes — Therapeutic Oligonucleotides



In the near term, progress will be measured by reliable extrahepatic delivery, potency gains without added class toxicity, and interval-friendly regimens that preserve adherence and access. These are the outcomes most likely when chemistry and delivery are co-designed with PK/PD modelling from the start.[5,6]

Conclusions

Therapeutic oligonucleotides have crossed from proof-of-concept to standard clinical practice across multiple indications, with modality-specific pharmacology that is now predictable enough for interval-driven dosing. In neurology, intrathecal splice-switching established durable CNS benefit with month-scale tissue half-lives and procedure-dominated safety. In systemic protein misfolding, both RNase-H ASOs and LNP-siRNA delivered large, clinically meaningful TTR reductions using distinct operational models i.e., weekly SC with lab monitoring versus intermittent IV with premedication.

For hepatocyte targets, GalNAc-siRNA converted small, infrequent subcutaneous doses into robust and durable pharmacodynamics—ALA suppression ~80–90% with attack reduction in AHP and ~50% LDL-C lowering with twice-yearly maintenance in hypercholesterolemia—anchoring the principle that intracellular residence, not plasma t½, sets dosing cadence. Population-scale mRNA vaccination validated N1-methylpseudouridine + LNP design for rapid expression and reliable safety, establishing a manufacturable platform for future therapeutic mRNA.

Across classes, chemistry defines stability, affinity, and innate immune profile, while delivery determines cell access and durability; together they set potency, interval, and monitoring needs. The field's next step is reliable extrahepatic targeting, potency gains without added class toxicity, and co-designed chemistry–delivery guided by quantitative PK/PD models—directions already mapped by state-of-the-art reviews and translational datasets.

References

1. Hofman CR, Corey DR. Targeting RNA with synthetic oligonucleotides: Clinical success invites new

challenges. Vol. 31, Cell Chemical Biology. 2024.
2. Mangla P, Vicentini Q, Biscans A. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking. Vol. 12, Cells. 2023.
3. Bellosta S, Rossi C, Alieva AS, Catapano AL, Corsini A, Baragetti A. Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review. Vol. 37, Cardiovascular Drugs and Therapy. 2023.
4. Gareri C, Polimeni A, Giordano S, Tammè L, Curcio A, Indolfi C. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. Vol. 11, Journal of Clinical Medicine. 2022.
5. Collotta D, Bertocchi I, Chiapello E, Collino M. Antisense oligonucleotides: a novel frontier in pharmacological strategy. Front Pharmacol. 2023;14:1304342.
6. Rogers H, Loftus DJ, Bruckner J V, Nguyen HQN. Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018. Clin Transl Sci. 2021;14(4):1647–57.
7. McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al. Nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metabolism and Disposition. 2022;50(6):781–97.
8. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383(27):2603–15.
9. Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B, et al. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025;10(1):73.
10. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen A V, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018;379(1):11–21.
11. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine. 2017;377(18):1723–32.
12. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018;379(1):22–31.
13. Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. New England Journal of Medicine. 2020;382(24):2289–301.
14. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. New England Journal of Medicine. 2020;382(16):1507–19.
15. Yang C, Jiang Y, Hao SH, Yan XY, Hong DF, Naranmandura H. Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy. Vol. 10, Journal of Materials Chemistry B. 2022.
16. Cruz-Hernández CD, Rodríguez-Martínez G, Cortés-Ramírez SA, Morales-Pacheco M, Cruz-Burgos M, Losada-García A, et al. Aptamers as Theragnostic Tools in Prostate Cancer. Vol. 12, Biomolecules. 2022.

17. Gholikhani T, Kumar S, Valizadeh H, Mahdinloo S, Adibkia K, Zakeri-Milani P, et al. Advances in Aptamers-Based Applications in Breast Cancer: Drug Delivery, Therapeutics, and Diagnostics. Vol. 23, International Journal of Molecular Sciences. 2022.
18. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: New tools for targeted cancer therapy. Vol. 3, Molecular Therapy Nucleic Acids. 2014.
19. Mahmoudian F, Ahmari A, Shabani S, Sadeghi B, Fahimirad S, Fattahi F. Aptamers as an approach to targeted cancer therapy. Vol. 24, Cancer Cell International. 2024.
20. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Vol. 23, Nature Reviews Genetics. 2022.
21. Dickey AK, Wheeden K, Lyon D, Nance D. Givosiran: a targeted treatment for acute intermittent porphyria. Hematology Am Soc Hematol Educ Program. 2024;2024(1):426–33.
22. Kim T, Croce CM. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Vol. 55, Experimental and Molecular Medicine. 2023.
23. Goyenvalle A, Leumann C, Garcia L. Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides. Vol. 3, Journal of Neuromuscular Diseases. 2016.
24. Kuespert S, Heydn R, Peters S, Wirkert E, Meyer AL, Siebörger M, et al. Antisense oligonucleotide in LNA-gapmer design targeting TGFBR2 – A key single gene target for safe and effective inhibition of TGFβ signaling. Int J Mol Sci. 2020;21(6).
25. Bravo-Vázquez LA, Paul S, Colín-Jurado MG, Márquez-Gallardo LD, Castañón-Cortés LG, Banerjee A, et al. Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases. Vol. 15, Genes. 2024.
26. Zhou LY, Qin Z, Zhu YH, He ZY, Xu T. Current RNA-based Therapeutics in Clinical Trials. Curr Gene Ther. 2019;19(3).
27. Yang H, Liu Y, Chen L, Zhao J, Guo M, Zhao X, et al. MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges? Vol. 13, Biomolecules. 2023.
28. Kim YK. RNA therapy: rich history, various applications and unlimited future prospects. Vol. 54, Experimental and Molecular Medicine. 2022.
29. Xiao M, Zhao J, Wang Q, Liu J, Ma L. Recent Advances of Degradation Technologies Based on PROTAC Mechanism. Vol. 12, Biomolecules. 2022.
30. Kruspe S, Giangrande PH. Aptamer-siRNA chimeras: Discovery, progress, and future prospects. Vol. 5, Biomedicines. 2017.